7-hydroxymitragynine (7-OH) is a naturally occurring compound derived from the kratom plant that some individuals use as a harm-reduction alternative to traditional opioids.
- manage chronic pain
- reduce opioid cravings
- support recovery from addiction
- provide an alternative to stronger prescription opioids
Responsible FDA-guided regulation, including clear labeling, manufacturing standards, and dosage guidelines, can help ensure these products remain safe while preserving access for the people who rely on them.
Proper oversight protects public health without removing a tool that may help people move away from dangerous opioids.
7-hydroxymitragynine (often called 7-OH) is a naturally derived compound found in the kratom plant. It interacts with some of the same receptors in the brain that opioids do, but many patients and veterans report using it as a safer alternative to traditional painkillers and other addictive drugs. In lower, carefully measured amounts, people say it helps them manage chronic pain, anxiety, and cravings while still feeling clearheaded and in control. They describe it not as a way to “get high,” but as a harmreduction tool that lets them work, care for their families, and rebuild their lives.
Kratom is a plant, not a synthetic or semisynthetic opioid manufactured in a lab. User report that kratombased products take the edge off pain and withdrawal without knocking them out, allowing them to stay functional, present, and engaged in work and relationships. That’s why so many see it as part of a harmreduction path away from more dangerous substances, not toward them.
7‑Hydroxymitragynine (7‑OH) is pharmacologically distinct from heroin, morphine, or fentanyl. It’s more comparable to buprenorphine, the medication used in opioid addiction treatment. Studies show that 7‑OH acts as a partial agonist at the μ‑opioid receptor rather than a full agonist like morphine or fentanyl. It’s also a G‑protein‑biased ligand, meaning it favors signaling pathways associated with analgesia over those linked to side effects such as respiratory depression. Because it is a partial agonist, 7‑OH exhibits a “ceiling effect” on opioid‑like effects—similar to buprenorphine—reducing the risk of severe respiratory suppression or overdose.
Kratom and kratomderived products occupy a patchwork legal landscape in the United States. Some states have chosen to ban or heavily restrict them, while others allow them with few or no guardrails. In many places, kratom and 7-OH products can be found in vape shops or gas stations, where quality and strength may not be consistently monitored. This “all or nothing” approach doesn’t serve public safety: instead of bans on one side and a free-for-all on the other, Americans deserve clear, science-based rules—like warning labels, potency limits, and quality controls—implemented through responsible FDA style regulation.
Many people who have struggled with heroin, fentanyl, and prescription painkillers say kratom and 7-OH have been crucial in getting them through withdrawal and staying off opioids. After trying methadone, Suboxone, or repeated stints in rehab, some individuals report that carefully dosed 7-OH helped quiet their cravings and manage pain enough to return to work, repair relationships, and remain abstinent from opioids. Others say it allowed them to step down from multiple substances—alcohol, cannabis, and sleep medications—while feeling more like themselves, not sedated. While no single option works for everyone and responsible use is essential, these realworld stories are exactly why policymakers should study and regulate kratom-derived products as a legitimate harm-reduction tool, rather than taking them away from people who are using them to escape addiction.